.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
UBS
Accenture
Boehringer Ingelheim
Chinese Patent Office
Cerilliant
Queensland Health
Baxter
Chubb
US Department of Justice

Generated: June 22, 2017

DrugPatentWatch Database Preview

Canagliflozin; metformin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for canagliflozin; metformin hydrochloride and what is the scope of canagliflozin; metformin hydrochloride patent protection?

Canagliflozin; metformin hydrochloride
is the generic ingredient in two branded drugs marketed by Janssen Pharms and is included in two NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Canagliflozin; metformin hydrochloride has two hundred and eight patent family members in forty-three countries.

There are eighteen drug master file entries for canagliflozin; metformin hydrochloride. One supplier is listed for this compound.

Summary for Generic Name: canagliflozin; metformin hydrochloride

Tradenames:2
Patents:7
Applicants:1
NDAs:2
Drug Master File Entries: see list18
Suppliers / Packagers: see list1
Clinical Trials: see list3,971
Drug Prices:see low prices
DailyMed Link:canagliflozin; metformin hydrochloride at DailyMed

Pharmacology for Ingredient: canagliflozin; metformin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-003Aug 8, 2014RXYesNo7,943,582► SubscribeYY ► Subscribe
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-002Aug 8, 2014RXYesNo8,785,403► SubscribeY ► Subscribe
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-002Sep 20, 2016RXYesNo7,943,582► SubscribeYY ► Subscribe
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-002Aug 8, 2014RXYesNo► Subscribe► Subscribe
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-002Sep 20, 2016RXYesNo7,943,788► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: canagliflozin; metformin hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,129,220Substituted indole-O-glucosides► Subscribe
8,202,984Glucopyranoside compound► Subscribe
7,511,020Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides► Subscribe
7,511,021Substituted indazole-O-glucosides► Subscribe
7,084,124Substituted indazole-O-glucosides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: canagliflozin; metformin hydrochloride

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2005011592► Subscribe
Canada2671357► Subscribe
Eurasian Patent Organization010655► Subscribe
World Intellectual Property Organization (WIPO)2005012318► Subscribe
Japan5065135► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014008,C1651658Lithuania► SubscribePRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115
90027-8Sweden► SubscribePRODUCT NAME: KANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001 20131115
2014 00024Denmark► SubscribePRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
14/029Ireland► SubscribePRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
0140011 00102Estonia► SubscribePRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
US Army
Medtronic
Deloitte
QuintilesIMS
Merck
Baxter
Dow
Cerilliant
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot